title: [Clinical observations of negative pressure wound therapy and basic fibroblast growth factor in the treatment of intractable pressure ulcer].
abstract: OBJECTIVE
  To observe the clinical efficacies and costs of negative pressure wound therapy (NPWT) and basic fibroblast growth factor (bFGF) in the treatment of stage III or IV pressure ulcer (PU).
  
  
  METHODS
  From July 2008 to December 2011, 48 patients fulfilling the study inclusion or exclusion criteria at Weihai Municipal Hospital were divided randomly into experiment and control groups (n=24 each). On the basis of routine treatment and NPWT of each inpatient, the patients in the experiment group were treated with bFGF. The changes of healing rate of PU were measured at Days 7 and 14 post-treatment in each group. Meanwhile, the granulation duration, preoperative time and total preoperative cost were compared.
  
  
  RESULTS
  The granulation duration, healing rate of Days 7 and 14, preoperative time and total preoperative cost in the experiment group was (10.8±2.7) days, 10.1%±2.9%, 22.3%±3.1%, (18.2±2.6) days and (7946±245) yuan RMB versus (16.3±3.9) days, 6.9%±1.9%, 13.4%±2.8%, (27.1±3.3) days and (10,951±285) yuan RMB in the control group respectively. The differences between two groups were statistically significant (all P<0.01).
  
  
  CONCLUSIONS
  As a preoperative therapeutic modality of intractable PU, NPWT and bFGF offer better therapeutic efficacies and lower therapeutic costs as compared with NPWT alone.
authors.affiliation: Department of Burns, Plastic & Cosmetic Surgery, Affiliated Weihai Municipal Hospital, Dalian Medical University, Weihai 264200, China.
authors.forename: Cheng
authors.initials: C
authors.lastname: Zhang
authors.forename: Jin-cun
authors.initials: JC
authors.lastname: Yang
authors.forename: Yong-qiang
authors.initials: YQ
authors.lastname: Feng
authors.forename: Hai-tao
authors.initials: HT
authors.lastname: Wang
authors.forename: Xia
authors.initials: X
authors.lastname: Li
authors.forename: Ning-jie
authors.initials: NJ
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D054843:Negative-Pressure Wound Therapy; D003668:Pressure Ulcer / Q000628:therapy*; D014945:Wound Healing
chemical_list: D016222:Fibroblast Growth Factor 2